Abstract
Purpose: To assess the safety and efficacy of a 3-day schedule of cisplatin and topotecan in patients with recurrent small-cell lung cancer (SCLC). Methods: Thirty-four relapsed patients were treated with cisplatin 20 mg/m2 and topotecan 0.9 mg/m2, both given on days 1–3 every 3 weeks, in a phase II study. Results: Complete response (CR) was achieved in two patients (6%), partial response (PR) in 4 (12%), stable disease in 6 (18%) and progressive disease in 14 (41%). Eight patients (23%) were non-evaluable for response. Among 21 sensitive patients, 2 (9.5%) achieved CR and 3 (14%) PR. Among 13 refractory patients, none achieved CR and only 1 (8%) PR. Median survival was 6.5 months for all patients, 7.8 for sensitive and 6.2 for refractory. Median time to progression (TTP) was 4.4 months for all patients, 5.9 for sensitive and 3.2 for refractory. Grade 3–4 toxicities included anemia (15%), thrombocytopenia (15%), neutropenia (42%), nausea/vomiting (3%), and alopecia (6%). No toxic death occurred. Conclusions: This 3-day schedule was well tolerated, produced modest response rates but good survival and TTP both in sensitive and refractory patients with relapsed SCLC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J (1997) Topotecan, a new active drug in the second-line treatment of small cell lung cancer (SCLC): a phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090–2096
Ardizzoni A, Manegold C, Bebruyne C, Gaafar R, Buchholts E, Smit E, Lianes P, ten Velde G, Bosquee L, Legran C, Neumaier C, King K, Giaccone G (2003) European Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 9:143–150
Briasoulis E, Karavasilis V, Tzamakou E, Rammou D, Pavlidis N (1999) Phase I trial of a three-day schedule of cisplatin plus topotecan. Eur J Cancer 35(suppl 4):291
Depierre A, Von Pawel J, Hanks K, Moro D, Clark P, Gatzemeier U, Paillot N, Scheithauer W, Carmichael J, Santoro A (1997) Evaluation of topotecan (Hycamtin) in relapsed small cell lung cancer (SCLC): a multicenter phase II study (Abstract). Lung Cancer 18:35
Eckardt JR, Palmer MC, Fanucci MP, Gralla R, Martins H., Poulin R, Fields SZ (2000) Single agent oral topotecan as first-line treatment for patients with extensive disease small cell lung cancer ineligible for standard therapy: a phase II study (Abstract). Lung Cancer 29:10
Eckardt J, von Pawel J, Hairsworth J et al (2003) Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemosensitive small cell lung cancer (SCLC). An international phase III study (abstract no. 2488) Proc Am Soc Clin Oncol 22:619
Figoli F, Venonesi A, Ardizzoni A, Canobbio L, Bruschi G, Mazza F, Zagonel V, Lo Re G, Rosso R, Monfardini S (1988) Cisplatin and etoposide as second line chemotherapy in patients with small cell lung cancer. Cancer Investig 6:1–5
Glisson BS (2003) Recurrent small cell lung cancer: update. Semin Oncol 30:72–78
Grant SC, Gralla RJ, Kriss MG, Orazem J, Kitsis EA (1992) Single agent chemotherapy trials in small cell lung cancer 1970–1990: the case for studies in previously treated patients. J Clin Oncol 10:484–498
Johnson RK, Mccabe FL, Young Y (1992) Combination regimens with topotecan in animal tumor models. Ann Oncol 3(Suppl 1):85
Kaplan EL, Meier P (1958) Non-parametric estimation for incomplete observations. J Am Stat Assoc 53:457–481
Moore TD, Korn EL (1992) Phase II trial design considerations for small-cell lung cancer. J Natl Cancer Inst 84:150
Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91
Perez-Soler R, Glisson BS, Lee JS, Fosella FV, Murphy WK, Shin DM, Hong WK (1996) Treatment of patients with small cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14:2785–2790
Simon G, Ginsberg RJ, Ruckdeschel JC (2001) Small cell lung cancer. Chest Surg Clin N Am 11:165–188
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10
Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas F et al (1994) Randomized comparison of etoposide-Cisplatin versus etoposide–carboplatin and irradiation in small cell lung cancer. Ann Oncol 5:601–607
Sundstrom S, Bremnes RM, Kaasa S et al (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol 20:4665–72
Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R (1999) Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol 17:658–667
WHO Handbook for Reporting Results of Cancer Treatment (1979) WHO Offset Publication No 48. Geneva
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Christodoulou, C., Kalofonos, H.P., Briasoulis, E. et al. Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG). Cancer Chemother Pharmacol 57, 207–212 (2006). https://doi.org/10.1007/s00280-005-0034-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-005-0034-3